AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11763937 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Cavity Fighting Toothpaste with Fluoristat (0.243% sodium fluoride)
Number of subjects: 2479
Study 11763937 — intervention group
Group type: COMPARATOR
Intervention: Colgate Great Regular Flavor Fluoride Toothpaste (0.76% sodium monofluorophosphate)
Number of subjects: 2479
Study 9279175 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive nutritional regimen (group A)
Number of subjects: 125
Study 9279175 — intervention group
Group type: COMPARATOR
Intervention: Conservative nutritional regimen (group B)
Number of subjects: 125
Study 8326972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg orally three times a day for 12 weeks
Number of subjects: 207
Study 8326972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 10 mg orally three times a day for 12 weeks
Number of subjects: 207
Study 8326972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 3551671 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline nebulization (2 ml saline t.i.d.)
Number of subjects: 20
Study 3551671 — intervention group
Group type: COMPARATOR
Intervention: Bromhexine nebulization (2 ml bromhexine, 2 mg/ml t.i.d.)
Number of subjects: 20
Study 3551671 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline nebulization
Number of subjects: 20
Study 3551671 — intervention group
Group type: COMPARATOR
Intervention: Bromhexine nebulization
Number of subjects: 20
Study 30720795 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention program
Number of subjects: 464
Study 30720795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 464
Study 27250851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training three times per week for 10 weeks before assisted fertilization
Number of subjects: 140
Study 27250851 — intervention group
Group type: COMPARATOR
Intervention: Standard care assisted fertilization only
Number of subjects: 140
Study 24519745 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1175
Study 24519745 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Materials (WM)
Number of subjects: 1175
Study 24519745 — intervention group
Group type: EXPERIMENTAL
Intervention: Videocassette and Written Materials (VC)
Number of subjects: 1175
Study 23252004 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI 28.0 kg/m2)
Number of subjects: 421
Study 23252004 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients (18.5 kg/m2 < or = BMI < 24.0 kg/m2)
Number of subjects: 421
Study 23252004 — intervention group
Group type: COMPARATOR
Intervention: Overweight patients (24.0 kg/m2 < or = BMI < 28.0 kg/m2)
Number of subjects: 421
Study 21268547 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg (E250)
Number of subjects: 80
Study 21268547 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg (E500)
Number of subjects: 80
Study 21268547 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg (M)
Number of subjects: 80
Study 21268547 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg (Z)
Number of subjects: 80
Study 18687718 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate
Number of subjects: 580
Study 18687718 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstimulated intrauterine insemination
Number of subjects: 580
Study 18687718 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 580
Study 15804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing oscillations between 3 and 16 Hz
Number of subjects: 0
Study 12576259 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg per day
Number of subjects: 59
Study 12576259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12576259 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label gabapentin dosing (up to 2,700 mg per day)
Number of subjects: 59
Study 10738641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincamine test product (60 mg single dose)
Number of subjects: 16
Study 10738641 — intervention group
Group type: COMPARATOR
Intervention: Vincamine reference product (60 mg single dose)
Number of subjects: 16
Study 8646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day regimen
Number of subjects: 0
Study 8646829 — intervention group
Group type: COMPARATOR
Intervention: Three-times-a-day regimen
Number of subjects: 0
Study 8646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 0
Study 8646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses taken at prescribed frequency
Number of subjects: 0
Study 8646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses taken at prescribed intervals
Number of subjects: 0
Study 2056895 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound treatment at 0.0 W.cm‐2
Number of subjects: 7
Study 2056895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment at 1.5 W.cm‐2, pulsed 50%
Number of subjects: 7
Study 2056895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment at 1.5 W.cm‐2, continuous
Number of subjects: 7
Study 6405876 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol combined with 12.5 mg hydrochlorothiazide
Number of subjects: 2
Study 6405876 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol combined with 25 mg hydrochlorothiazide
Number of subjects: 2
Study 6405876 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol combined with 50 mg hydrochlorothiazide
Number of subjects: 2
Study 6405876 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of hydrochlorothiazide
Number of subjects: 2
Study 31090674 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week dietary intervention monitored by health professionals
Number of subjects: 102
Study 29572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fractionated radiotherapy (RT)
Number of subjects: 555
Study 29572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 555
Study 29572674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fractionated RT and chemotherapy
Number of subjects: 555
Study 29572674 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvant treatment
Number of subjects: 555
Study 26929219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab infusions at 4-week intervals (3 infusions total) followed by oral prednisone from weeks 12 to 24 (0.15 mg/kg if PMR-AS ≤10 and 0.30 mg/kg otherwise)
Number of subjects: 20
Study 26929219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab infusions
Number of subjects: 20
Study 25227538 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with standard rehabilitation (SR)
Number of subjects: 37
Study 25227538 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (SR)
Number of subjects: 37
Study 23019949 — intervention group
Group type: EXPERIMENTAL
Intervention: Jing'an Oral Liquid (JOL)
Number of subjects: 60
Study 23019949 — intervention group
Group type: COMPARATOR
Intervention: Tiapride Tablet (TT)
Number of subjects: 60
Study 20500251 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia Learning Education Program (MLEP)
Number of subjects: 58
Study 20500251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MLEP)
Number of subjects: 58
Study 17935230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg/day from day 7 to day 21 and 1 mg/kg/day from day 22 to day 28)
Number of subjects: 71
Study 17935230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 71
Study 15598455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic radiostereometry during weight-bearing active extension in OA patients
Number of subjects: 24
Study 15598455 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 controls)
Number of subjects: 24
Study 11895960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (2 x 10^8 CFU)
Number of subjects: 59
Study 11895960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CeraVacx buffer)
Number of subjects: 59
Study 9462488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch for 10 weeks as an adjunct to brief counseling
Number of subjects: 410
Study 9462488 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 410
Study 7637364 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy plus dipyridamole (225 to 400 mg per day)
Number of subjects: 1141
Study 7637364 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy alone
Number of subjects: 1141
Study 7637364 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy plus dipyridamole
Number of subjects: 1141
Study 2087819 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet about endoscopic investigations
Number of subjects: 379
Study 2087819 — intervention group
Group type: COMPARATOR
Intervention: No information booklet (control group)
Number of subjects: 379
Study 6218101 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin plus sisomicin (Regimen A)
Number of subjects: 49
Study 6218101 — intervention group
Group type: COMPARATOR
Intervention: cefamandole plus tobramycin (Regimen B)
Number of subjects: 49
Study 6218101 — intervention group
Group type: EXPERIMENTAL
Intervention: empiric Regimen C (cefotaxime plus amikacin plus azlocillin)
Number of subjects: 49
Study 6218101 — intervention group
Group type: EXPERIMENTAL
Intervention: antibiotics selected on the basis of bacteriological results (Regimen D)
Number of subjects: 49
Study 31104217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein
Number of subjects: 40
Study 31104217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28864483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 0
Study 28864483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine immobilisation
Number of subjects: 0
Study 27748671 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS at 80% resting motor threshold (RMT)
Number of subjects: 0
Study 27748671 — intervention group
Group type: COMPARATOR
Intervention: iTBS at 40% resting motor threshold (RMT)
Number of subjects: 0
Study 24635872 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P: Positive Parenting Program (SSTP) with Acceptance and Commitment Therapy (ACT) workshop
Number of subjects: 59
Study 24635872 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 59
Study 23031082 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 200
Study 23031082 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 200
Study 23031082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients with delayed graft function
Number of subjects: 200
Study 23031082 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients without delayed graft function
Number of subjects: 200
Study 19650919 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health promotion campaign and education through health clubs, intensive training and mentoring of village health workers, improved outreach services.
Number of subjects: 146
Study 17501846 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 72
Study 16941337 — intervention group
Group type: COMPARATOR
Intervention: Acute treatment (HAART initiated within 2 weeks of seroconversion)
Number of subjects: 395
Study 16941337 — intervention group
Group type: COMPARATOR
Intervention: Early treatment (HAART initiated between 2 weeks and 6 months after seroconversion)
Number of subjects: 395
Study 16941337 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated group (no HAART)
Number of subjects: 395
Study 12860535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine
Number of subjects: 13
Study 12860535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study 10896032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10mg)
Number of subjects: 9
Study 10896032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5mg)
Number of subjects: 9
Study 9034935 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus UDCA
Number of subjects: 52
Study 9034935 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 52
Study 1991274 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly chest radiography plus sputum cytology every 4 months
Number of subjects: 0
Study 1991274 — intervention group
Group type: COMPARATOR
Intervention: Yearly chest radiography only
Number of subjects: 0
Study 1991274 — intervention group
Group type: COMPARATOR
Intervention: Advice to obtain chest radiography and sputum cytology once a year
Number of subjects: 0
Study 6338415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide (Amipaque)
Number of subjects: 100
Study 6338415 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (Niopam)
Number of subjects: 100
Study 30327396 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based progression (PBP) training (Group P)
Number of subjects: 17
Study 30327396 — intervention group
Group type: COMPARATOR
Intervention: Simulation only training (Group S)
Number of subjects: 17
Study 27498099 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly module group
Number of subjects: 492
Study 27498099 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly module group
Number of subjects: 492
Study 27498099 — intervention group
Group type: COMPARATOR
Intervention: Single module group
Number of subjects: 492
Study 23968289 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (window outlining technique)
Number of subjects: 72
Study 23968289 — intervention group
Group type: COMPARATOR
Intervention: Group B (ultrasonic erosion technique)
Number of subjects: 72
Study 23102903 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified antithrombin supplementation to reach an antithrombin activity value of 120%
Number of subjects: 200
Study 23102903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antithrombin supplementation)
Number of subjects: 200
Study 23102903 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified antithrombin supplementation
Number of subjects: 200
Study 19940233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 15
Study 19940233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 15
Study 19940233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg plus Rabeprazole 10 mg
Number of subjects: 15
Study 19940233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19940233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg (once daily)
Number of subjects: 15
Study 19940233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg (4 times per day)
Number of subjects: 15
Study 17881004 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% CO(2) challenge
Number of subjects: 404
Study 17881004 — intervention group
Group type: COMPARATOR
Intervention: Control for gender and trait anxiety
Number of subjects: 404
Study 16172491 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS)
Number of subjects: 0
Study 16172491 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine plus erythromycin (SP plus E)
Number of subjects: 0
Study 16172491 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely malnourished children
Number of subjects: 0
Study 12576938 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg/day) administered as a 30-min intravenous infusion for 5 days or until white blood cell count reached >75.0 x 10(9) cells/L
Number of subjects: 0
Study 12576938 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotic therapy with filgrastim
Number of subjects: 0
Study 12576938 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy with placebo
Number of subjects: 0
Study 12576938 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0
Study 10389953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg intravenous (IV) ketorolac
Number of subjects: 29
Study 10389953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8678098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 hours
Number of subjects: 882
Study 8678098 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 hours
Number of subjects: 882
Study 8678098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftazidime
Number of subjects: 882
Study 1878532 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS-1
Number of subjects: 0
Study 1878532 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS-2
Number of subjects: 0
Study 1878532 — intervention group
Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 0
Study 1878532 — intervention group
Group type: EXPERIMENTAL
Intervention: GMS formulation (multiple dosing)
Number of subjects: 0
Study 6849731 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 6
Study 6849731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 6
Study 6849731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (25 mg)
Number of subjects: 6
Study 6849731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31031180 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB)‐driven message
Number of subjects: 160
Study 26751602 — intervention group
Group type: EXPERIMENTAL
Intervention: Conically shaped interdental brushes
Number of subjects: 51
Study 26751602 — intervention group
Group type: COMPARATOR
Intervention: Cylindrically shaped interdental brushes
Number of subjects: 51
Study 26751602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IDB types
Number of subjects: 51
Study 25327222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemongrass mouthrinse
Number of subjects: 20
Study 23524015 — intervention group
Group type: EXPERIMENTAL
Intervention: extrafine BDP/F 400/24 μg/day pMDI
Number of subjects: 416
Study 23524015 — intervention group
Group type: COMPARATOR
Intervention: FP/S 500/100 μg/day Diskus®
Number of subjects: 416
Study 20975611 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor group
Number of subjects: 20
Study 20975611 — intervention group
Group type: COMPARATOR
Intervention: No angiotensin-converting enzyme inhibitor group
Number of subjects: 20
Study 19118243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation (5 mg folic acid + 0.4 mg vitamin B12 + 50 mg vitamin B6)
Number of subjects: 506
Study 19118243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 19118243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation
Number of subjects: 506
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Hydrochlorothiazide (150 mg + 25 mg)
Number of subjects: 67
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Ramipril (75 mg or 150 mg)
Number of subjects: 67
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Irbesartan (75 mg or 150 mg)
Number of subjects: 67
Study 17159081 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren (150 mg) alone
Number of subjects: 67
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Hydrochlorothiazide
Number of subjects: 67
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Ramipril
Number of subjects: 67
Study 17159081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren + Irbesartan
Number of subjects: 67
Study 15120684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam prophylaxis
Number of subjects: 110
Study 15120684 — intervention group
Group type: COMPARATOR
Intervention: No oral prophylaxis (Control)
Number of subjects: 110
Study 11100761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nitroglycerin (3 microg per kg heart weight per min)
Number of subjects: 46
Study 11100761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus nitroglycerin (2 mg into the aortic root)
Number of subjects: 46
Study 11100761 — intervention group
Group type: COMPARATOR
Intervention: Control (ctr)
Number of subjects: 46
Study 9211441 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI plus LRZ
Number of subjects: 49
Study 8249556 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine
Number of subjects: 30
Study 8249556 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nitrendipine
Number of subjects: 30
Study 8249556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3698063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociverine (20 mg)
Number of subjects: 40
Study 3698063 — intervention group
Group type: COMPARATOR
Intervention: Flavoxate (200 mg)
Number of subjects: 40
Study 30589349 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM)
Number of subjects: 50
Study 30589349 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 50
Study 30589349 — intervention group
Group type: EXPERIMENTAL
Intervention: IBM
Number of subjects: 50
Study 30589349 — intervention group
Group type: COMPARATOR
Intervention: PMR
Number of subjects: 50
Study 28378403 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 μg haemagglutinin vaccine
Number of subjects: 256
Study 28378403 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg haemagglutinin vaccine
Number of subjects: 256
Study 28378403 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 μg haemagglutinin vaccine
Number of subjects: 256
Study 28378403 — intervention group
Group type: COMPARATOR
Intervention: 15 μg haemagglutinin vaccine
Number of subjects: 256
Study 25175385 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 124
Study 25175385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124